Ledger.

Executive Director, Cincera Therapeutics

Dr Michael Bettess

Coverage

Stories naming Dr Michael Bettess. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

2 deals

Biomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions

Cincera Therapeutics has received a million-dollar Biomedical Translation Bridge grant to advance its Des-1 inhibitor drug for obesity-related metabolic diseases. The Monash and UniSA spin-out previously secured venture funding from the Medical Research Commercialisation Fund.

Brandon BioCatalyst portfolio Thu 3 Sep 2020 Cincera TherapeuticsBioCurateBrandon Capital PartnersBridge and BridgeTech programsCALHNCentre for Cancer BiologyFlinders UniversityMedical Device Partnering ProgramMedical Research Future FundMonash Institute of Pharmaceutical SciencesMonash UniversityMTPConnectQueensland University of TechnologyUniQuestUniSA Ventures Pty LtdUniversity of MelbourneUniversity of QueenslandUniversity of South AustraliaBiomedical Translation BridgeMedical Research Commercialisation Fund (MRCF)Associate Professor Bernard FlynnDr Michael BettessProfessor Stuart Pitson

Also Brandon Capital portfolio·cinceratx.com

Something wrong? Tell us